Mirum Pharmaceuticals (MIRM) Competitors $52.66 -0.35 (-0.66%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$53.50 +0.85 (+1.60%) As of 07/11/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MIRM vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTHShould you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Mirum Pharmaceuticals vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Lantheus Blueprint Medicines (NASDAQ:BPMC) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability. Which has stronger earnings and valuation, BPMC or MIRM? Blueprint Medicines has higher revenue and earnings than Mirum Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlueprint Medicines$508.82M16.41-$67.09M-$2.47-52.35Mirum Pharmaceuticals$336.89M7.74-$87.94M-$1.61-32.71 Do analysts prefer BPMC or MIRM? Blueprint Medicines presently has a consensus target price of $128.25, suggesting a potential downside of 0.81%. Mirum Pharmaceuticals has a consensus target price of $65.50, suggesting a potential upside of 24.38%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.24Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is BPMC or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -20.39% compared to Blueprint Medicines' net margin of -27.70%. Mirum Pharmaceuticals' return on equity of -33.63% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Blueprint Medicines-27.70% -64.60% -17.22% Mirum Pharmaceuticals -20.39%-33.63%-11.50% Which has more risk and volatility, BPMC or MIRM? Blueprint Medicines has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Does the media prefer BPMC or MIRM? In the previous week, Blueprint Medicines had 5 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 9 mentions for Blueprint Medicines and 4 mentions for Mirum Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.23 beat Mirum Pharmaceuticals' score of 1.02 indicating that Blueprint Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Blueprint Medicines 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMirum Pharmaceuticals beats Blueprint Medicines on 9 of the 14 factors compared between the two stocks. Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRM vs. The Competition Export to ExcelMetricMirum PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63B$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-32.7120.5827.9620.25Price / Sales7.74292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book11.207.638.045.49Net Income-$87.94M-$55.05M$3.18B$250.27M7 Day Performance5.47%8.54%3.67%4.80%1 Month Performance7.43%5.51%4.09%7.68%1 Year Performance33.52%2.03%29.58%16.36% Mirum Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRMMirum Pharmaceuticals2.9134 of 5 stars$52.66-0.7%$65.50+24.4%+39.8%$2.63B$336.89M-32.71140News CoveragePositive NewsAnalyst ForecastBPMCBlueprint Medicines1.0898 of 5 stars$128.18+0.1%$128.06-0.1%+9.8%$8.28B$562.12M-51.89640Positive NewsInsider TradeBBIOBridgeBio Pharma4.5827 of 5 stars$43.18-3.7%$58.85+36.3%+72.8%$8.20B$221.90M-12.23400Analyst UpgradeHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.3867 of 5 stars$94.58+0.8%$101.10+6.9%+394.0%$8.05B$42.28M-47.2930Trending NewsAnalyst ForecastROIVRoivant Sciences2.8211 of 5 stars$11.27-1.1%$17.50+55.3%+1.1%$7.66B$29.05M-45.08860Analyst UpgradeELANElanco Animal Health1.4943 of 5 stars$14.29flat$15.17+6.1%+9.0%$7.10B$4.44B19.319,000News CoverageRVMDRevolution Medicines4.5689 of 5 stars$36.79-0.3%$67.58+83.7%-12.3%$6.85B$11.58M-9.20250LEGNLegend Biotech3.3881 of 5 stars$35.49+2.5%$76.20+114.7%-19.7%$6.52B$627.24M-60.152,609Analyst ForecastGRFSGrifols3.6078 of 5 stars$9.04+2.0%$10.30+13.9%+10.1%$6.22B$7.81B7.7323,822News CoverageTGTXTG Therapeutics3.7912 of 5 stars$35.99-2.0%$40.80+13.4%+73.4%$5.71B$386.39M149.96290News CoveragePositive NewsAnalyst UpgradeLNTHLantheus4.5729 of 5 stars$81.86+0.5%$130.50+59.4%-34.2%$5.66B$1.53B23.26700Positive News Related Companies and Tools Related Companies Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Legend Biotech Competitors Grifols Competitors TG Therapeutics Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRM Stock Alerts